Tetraphase Pharmaceuticals Inc (TTPH) 10.20 $TTPH
Tetraphase Slumps: TTPH Falls 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:49AM CDT
Tetraphase Pharmaceuticals saw a big move last session, as the company’s shares fell by over 10% on the day
Tetraphase Pharmaceuticals, Inc. [TTPH] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Mon Apr 07, 9:00AM CDT
What:
Fast-Track Status for Tetraphase Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:05PM CDT
Shares of Tetraphase Pharma were up 2.5% after the company received Fast Track designation from FDA for its lead antibiotic candidate, eravacycline.
Tetraphase Pharmaceuticals' eravacycline awarded US FDA's Fast Track designation for two formulations and for two therapeutic indications
M2 - Thu Apr 03, 5:52AM CDT
Biopharmaceutical company Tetraphase Pharmaceuticals (NasdaqGS:TTPH) reported on Wednesday the receipt of the US Food & Drug Administration's (FDA) Fast Track designations for both the intravenous (IV) and oral formulations of its lead antibiotic candidate, eravacycline.
Why Tetraphase Pharmaceuticals Inc Shares Popped
Brian Pacampara, The Motley Fool - Motley Fool - Wed Apr 02, 11:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Tetraphase Pharmaceuticals Inc popped as...
FDA Awards Fast Track Status to Tetraphase Pharmaceuticals for IV and Oral Formulations of Eravacycline
Business Wire - Wed Apr 02, 7:33AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antibiotic candidate, eravacycline. Tetraphase is investigating the safety and efficacy of eravacycline in its ongoing Phase 3 global clinical program; the IGNITE 1 study is evaluating the IV formulation of eravacycline for the treatment of complicated intra-abdominal infections (cIAI); IGNITE 2 is evaluating eravacycline IV-to-oral step-down therapy for the treatment of complicated urinary tract infections (cUTI).
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
Tetraphase's Eravacycline Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 10:30AM CDT
Tetraphase is working hard to develop its pipeline.
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Fri Mar 21, 8:03AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against drug-resistant bacteria, today announced presentations at two upcoming investor conferences. The Company's lead antibiotic candidate, eravacycline, is currently in Phase 3 development to treat multidrug-resistant (MDR) infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 Lead Antibiotic Candidate Eravacycline
Business Wire - Thu Mar 20, 7:33AM CDT
--Enrollment underway in IGNITE 2 Phase 3 clinical trial of IV/oral eravacycline in complicated urinary tract infections
Tetraphase Pharmaceuticals Adds Nancy J. Wysenski to Board of Directors
Business Wire - Thu Mar 13, 7:35AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced the addition of Nancy J. Wysenski to the company's Board of Directors. Ms. Wysenski has more than 35 years' experience in the life science industry, the majority of which have been spent in commercial leadership roles.
What Falling Estimates & Price Mean for Tetraphase Pharmaceuticals (TTPH) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:15AM CDT
One such stock that you may want to consider dropping is Tetraphase Pharmaceuticals which witnessed negative earnings estimate revisions in current quarter and current year.
Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 06, 6:00AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.
Tularaemia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 18, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/5g72f2/tularaemia) has announced the addition of the "Tularaemia - Pipeline Review, H2 2013" report to their offering. 'Tularaemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tularaemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tularaemia. Scope - A snapshot of the global therapeutic scenario for Tularaemia. - A review of the Tularaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tularaemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Tularaemia Overview Therapeutics Development Pipeline Products for Tularaemia - Overview Pipeline Products for Tularaemia - Comparative Analysis Tularaemia - Therapeutics under Development by Companies Tularaemia - Therapeutics under Investigation by Universities/Institutes Tularaemia - Pipeline Products Glance Tularaemia - Products under Development by Companies Tularaemia - Products under Investigation by Universities/Institutes Tularaemia - Companies Involved in Therapeutics Development Tetraphase Pharmaceuticals Inc. Tularaemia - Therapeutics Assessment Drug Profiles gentamicin sulfate - Drug Profile Tularaemia Vaccine - Drug Profile TP-271 - Drug Profile Lm-Tularemia - Drug Profile Recombinant Tularemia Vaccine - Drug Profile Vaccine For Tularemia - Drug Profile DM-204 - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Nanotherapeutics, Inc. Aduro BioTech, Inc. DiaMedica Inc. Protein Potential, LLC EpiVax, Inc. Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5g72f2/tularaemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Tetraphase Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 05, 8:03AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11th at 3:00 p.m. Eastern Time. The conference will take place February 10 - 11 at the Waldorf Astoria in New York City.
Tetraphase Pharmaceuticals Inc appoints Craig Thompson as COO
M2 - Wed Feb 05, 4:05AM CST
Biopharmaceutical company Tetraphase Pharmaceuticals Inc (NasdaqGS:TTPH) reported on Tuesday the election of Craig Thompson as its chief operating officer.
Tetraphase Pharmaceuticals Names Craig Thompson Chief Operating Officer
Business Wire - Tue Feb 04, 7:35AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the appointment of Craig Thompson to the position of Chief Operating Officer, effective immediately. In his new role, Mr. Thompson, who most recently served as Chief Commercial Officer for Trius Therapeutics, will be responsible for leading Tetraphase's commercial operations, including business development and licensing, commercial planning and early marketing initiatives for eravacycline, Tetraphase's lead, late-stage antibiotic candidate. Tetraphase is developing eravacycline and a pipeline of early-stage antibiotic candidates to combat the growing public health threats from resistant Gram-negative infections.
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Tetraphase Slumps: TTPH Falls 10.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:49AM CDT
Tetraphase Pharmaceuticals saw a big move last session, as the company’s shares fell by over 10% on the day
Tetraphase Pharmaceuticals, Inc. [TTPH] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Mon Apr 07, 9:00AM CDT
What:
Fast-Track Status for Tetraphase Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 5:05PM CDT
Shares of Tetraphase Pharma were up 2.5% after the company received Fast Track designation from FDA for its lead antibiotic candidate, eravacycline.
Tetraphase Pharmaceuticals' eravacycline awarded US FDA's Fast Track designation for two formulations and for two therapeutic indications
M2 - Thu Apr 03, 5:52AM CDT
Biopharmaceutical company Tetraphase Pharmaceuticals (NasdaqGS:TTPH) reported on Wednesday the receipt of the US Food & Drug Administration's (FDA) Fast Track designations for both the intravenous (IV) and oral formulations of its lead antibiotic candidate, eravacycline.
Why Tetraphase Pharmaceuticals Inc Shares Popped
Brian Pacampara, The Motley Fool - Motley Fool - Wed Apr 02, 11:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Tetraphase Pharmaceuticals Inc popped as...
FDA Awards Fast Track Status to Tetraphase Pharmaceuticals for IV and Oral Formulations of Eravacycline
Business Wire - Wed Apr 02, 7:33AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designations for both the intravenous (IV) and oral formulations of the company's lead antibiotic candidate, eravacycline. Tetraphase is investigating the safety and efficacy of eravacycline in its ongoing Phase 3 global clinical program; the IGNITE 1 study is evaluating the IV formulation of eravacycline for the treatment of complicated intra-abdominal infections (cIAI); IGNITE 2 is evaluating eravacycline IV-to-oral step-down therapy for the treatment of complicated urinary tract infections (cUTI).
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
Tetraphase's Eravacycline Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 10:30AM CDT
Tetraphase is working hard to develop its pipeline.
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire - Fri Mar 21, 8:03AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against drug-resistant bacteria, today announced presentations at two upcoming investor conferences. The Company's lead antibiotic candidate, eravacycline, is currently in Phase 3 development to treat multidrug-resistant (MDR) infections, including those caused by many of the MDR Gram-negative bacteria highlighted as urgent public health threats by the Centers for Disease Control and Prevention (CDC).
Tetraphase Pharmaceuticals Provides Update on Clinical Progress of Phase 3 Lead Antibiotic Candidate Eravacycline
Business Wire - Thu Mar 20, 7:33AM CDT
--Enrollment underway in IGNITE 2 Phase 3 clinical trial of IV/oral eravacycline in complicated urinary tract infections
Tetraphase Pharmaceuticals Adds Nancy J. Wysenski to Board of Directors
Business Wire - Thu Mar 13, 7:35AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against multidrug-resistant bacteria, today announced the addition of Nancy J. Wysenski to the company's Board of Directors. Ms. Wysenski has more than 35 years' experience in the life science industry, the majority of which have been spent in commercial leadership roles.
What Falling Estimates & Price Mean for Tetraphase Pharmaceuticals (TTPH) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 8:15AM CDT
One such stock that you may want to consider dropping is Tetraphase Pharmaceuticals which witnessed negative earnings estimate revisions in current quarter and current year.
Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results
Business Wire - Thu Mar 06, 6:00AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.
Tularaemia - Pipeline Review, H2 2013 Research Report
M2 - Tue Feb 18, 2:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/5g72f2/tularaemia) has announced the addition of the "Tularaemia - Pipeline Review, H2 2013" report to their offering. 'Tularaemia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Tularaemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tularaemia. Scope - A snapshot of the global therapeutic scenario for Tularaemia. - A review of the Tularaemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Tularaemia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Tularaemia Overview Therapeutics Development Pipeline Products for Tularaemia - Overview Pipeline Products for Tularaemia - Comparative Analysis Tularaemia - Therapeutics under Development by Companies Tularaemia - Therapeutics under Investigation by Universities/Institutes Tularaemia - Pipeline Products Glance Tularaemia - Products under Development by Companies Tularaemia - Products under Investigation by Universities/Institutes Tularaemia - Companies Involved in Therapeutics Development Tetraphase Pharmaceuticals Inc. Tularaemia - Therapeutics Assessment Drug Profiles gentamicin sulfate - Drug Profile Tularaemia Vaccine - Drug Profile TP-271 - Drug Profile Lm-Tularemia - Drug Profile Recombinant Tularemia Vaccine - Drug Profile Vaccine For Tularemia - Drug Profile DM-204 - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Nanotherapeutics, Inc. Aduro BioTech, Inc. DiaMedica Inc. Protein Potential, LLC EpiVax, Inc. Tetraphase Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5g72f2/tularaemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Tetraphase Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
Business Wire - Wed Feb 05, 8:03AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing a portfolio of potent new antibiotics designed to be effective against dangerous, drug-resistant bacteria (including multidrug-resistant (MDR) Gram-negative pathogens), today announced that Guy Macdonald, Tetraphase President and Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11th at 3:00 p.m. Eastern Time. The conference will take place February 10 - 11 at the Waldorf Astoria in New York City.
Tetraphase Pharmaceuticals Inc appoints Craig Thompson as COO
M2 - Wed Feb 05, 4:05AM CST
Biopharmaceutical company Tetraphase Pharmaceuticals Inc (NasdaqGS:TTPH) reported on Tuesday the election of Craig Thompson as its chief operating officer.
Tetraphase Pharmaceuticals Names Craig Thompson Chief Operating Officer
Business Wire - Tue Feb 04, 7:35AM CST
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the appointment of Craig Thompson to the position of Chief Operating Officer, effective immediately. In his new role, Mr. Thompson, who most recently served as Chief Commercial Officer for Trius Therapeutics, will be responsible for leading Tetraphase's commercial operations, including business development and licensing, commercial planning and early marketing initiatives for eravacycline, Tetraphase's lead, late-stage antibiotic candidate. Tetraphase is developing eravacycline and a pipeline of early-stage antibiotic candidates to combat the growing public health threats from resistant Gram-negative infections.
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
